Advertisement

Fungal Infections in Cancer Patients

  • Yaşar Barış Turgut
  • Gökhan Sargın
  • Özgür Tanrıverdi
Chapter

Abstract

The incidence of invasive fungal diseases has increased due to increases in using immunosuppressive agents and organ or hematopoietic stem cell transplantation over the last decade. The infections are among the major causes of morbidity and mortality in patients with cancer. Solid and hematological malignancies, advanced age, hypoproteinemia, duration of hospital stay, chemotherapy, and especially neutropenia are important risk factors for fungal infections in patients with cancer. Considering these parameters, treatment with differential diagnosis and early diagnosis may improve prognosis, and this may lead to reduced mortality and morbidity.

Keywords

Amphotericin B Antifungal therapy Aspergillus Cytotoxic agents Invasive fungal disease Molds Solid malignancies Voriconazole Yeast-like fungi Zygomycetes 

Abbreviations

CNS

Central nervous system

MRI

Magnetic resonance imaging

References

  1. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S, Okudaira M, Scevola D, van’t Wout J. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99–109.CrossRefGoogle Scholar
  2. Calton EA, Le Doaré K, Appleby G, Chisholm JC, Sharland M, Ladhani SN, CABIN Participants. Invasive bacterial and fungal infections in paediatric patients with cancer: incidence, risk factors, aetiology and outcomes in a UK regional cohort 2009-2011. Pediatr Blood Cancer. 2014;61:1239–45.CrossRefGoogle Scholar
  3. CDC, Infectious Disease Society of America, the American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy. 2001;3:41–54.CrossRefGoogle Scholar
  4. Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow TransplantGroup (EBMT), American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), Association of Medical Microbiology and Infectious Diseases Canada (AMMI), Centers for Disease Control and Prevention (CDC). Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44:453–8.CrossRefGoogle Scholar
  5. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91:986–9.PubMedGoogle Scholar
  6. Chen K, Wang Q, Pleasants RA, Ge L, Liu W, Peng K, Zhai S. Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis. BMC Infect Dis. 2017;17:159.CrossRefGoogle Scholar
  7. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64:68–75.CrossRefGoogle Scholar
  8. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–37.CrossRefGoogle Scholar
  9. Douglas AP, Chen SC, Slavin MA. Emerging infections caused by non-Aspergillus filamentous fungi. Clin Microbiol Infect. 2016;22:670–80.CrossRefGoogle Scholar
  10. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefGoogle Scholar
  11. Haßler A, Porto L, Lehrnbecher T. Cerebral fungal infection in pediatric cancer patients. Curr Fungal Infect Rep. 2015;9:6–14.CrossRefGoogle Scholar
  12. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U, Kubin T, Penack O, Reichert D, Reuter S, Silling G, Südhoff T, Ullmann AJ, Maschmeyer G. Treatment of invasive fungal infections in cancer patients—recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009;88:97–110.CrossRefGoogle Scholar
  13. Kappagoda S, Adams JY, Luo R, Banaei N, Concepcion W, Ho DY. Fatal Emmonsia sp. infection and fungemia after orthotopic liver transplantation. Emerg Infect Dis. 2017;23:346–9.CrossRefGoogle Scholar
  14. Krishnan NS. Emerging fungal infections in cancer patients- a brief overview. Med Mycol. 2016;2:16.  https://doi.org/10.21767/2471-8521.100016.CrossRefGoogle Scholar
  15. Lortholary O, Charlier C, Lebeaux D, Lecuit M, Consigny PH. Fungal infections in immunocompromised travelers. Clin Infect Dis. 2013;56:861–9.CrossRefGoogle Scholar
  16. Malani AN, Kauffman CA. Changing epidemiology of rare mold infections: implications for therapy. Drugs. 2007;67(13):1803–12.CrossRefGoogle Scholar
  17. Mcneil MM. Trends in mortality due to invasive aspergillosis in the United States 1980-1997. Clin Infect Dis. 2001;33:641–7.CrossRefGoogle Scholar
  18. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5–14.CrossRefGoogle Scholar
  19. Peghin M, Monforte V, Martin-Gomez MT. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients. Transpl Infect Dis. 2016;18:70–8.CrossRefGoogle Scholar
  20. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3–S14.CrossRefGoogle Scholar
  21. Pu S, Niu S, Zhang C, Xu X, Qin M, Huang S, Zhang L. Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China. J Microbiol Immunol Infect. 2017;50:97–103.CrossRefGoogle Scholar
  22. Ribaud P. Fungal infections and the cancer patient. Eur J Cancer. 1997;33(suppl 4):S50–4.CrossRefGoogle Scholar
  23. Salmeron G, Porcher R, Bergeron A, Robin M, Peffault de Latour R, Ferry C, Rocha V, Petropoulou A, Xhaard A, Lacroix C, Sulahian A, Socié G, Ribaud P. Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis. Haematologica. 2012;97:1357–63.CrossRefGoogle Scholar
  24. Schwartz IS, Kenyon C, Feng P, Govender NP, Dukik K, Sigler L, Jiang Y, Stielow JB, Muñoz JF, Cuomo CA, Botha A, Stchigel AM, de Hoog GS. 50 years of Emmonsia disease in humans: the dramatic emergence of a cluster of novel fungal pathogens. PLoS Pathog. 2015;11:e1005198.CrossRefGoogle Scholar
  25. Sekhon AS, Jackson FL, Jacobs HJ. Blastomycosis: report of the first case from Alberta, Canada. Mycopathologia. 1982;79:65–9.CrossRefGoogle Scholar
  26. Stanzani M, Sassi C, Battista G, Cavo M, Lewis RE. Improved radiographic imaging of invasive fungal disease: the cornerstone to antifungal stewardship in the hematology units? Curr Fungal Infect Rep. 2016;10:78–86.CrossRefGoogle Scholar
  27. Starkey J, Moritani T, Kirby P. MRI of CNS fungal infections: review of aspergillosis to histoplasmosis and everything in between. Clin Neuroradiol. 2014;24:217–30.CrossRefGoogle Scholar
  28. Wang H, Liu N, Yin M, Han H, Yue J, Zhang F, Shan T, Guo H, Wu D. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study. BMC Infect Dis. 2014;14:609.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Yaşar Barış Turgut
    • 1
  • Gökhan Sargın
    • 2
  • Özgür Tanrıverdi
    • 3
  1. 1.Department of Internal MedicineMuğla Sıtkı Koçman University School of MedicineMuğlaTurkey
  2. 2.Department of Internal MedicineAydın Adnan Menderes University School of MedicineAydınTurkey
  3. 3.Division of Medical OncologyMuğla Sıtkı Koçman University School of MedicineMuğlaTurkey

Personalised recommendations